| NCT02431676
| Survivorship Promotion In Reducing IGF-1 Trial | | prevention | 2 | completed |
| NCT05169957
| Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) | | treatment | 1 | active_not_recruiting |
| NCT01728051
| Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver | | Not Available | Not Available | no_longer_available |
| NCT06008977
| Exercise to Boost Response to Checkpoint Blockade Immunotherapy | No drug interventions | other | Not Available | recruiting |
| NCT05970497
| A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | No drug interventions | treatment | 1 | recruiting |
| NCT05219578
| RTX-224 Monotherapy in Patients With Solid Tumors | No drug interventions | treatment | 1 / 2 | terminated |
| NCT04254107
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | | treatment | 1 | terminated |
| NCT04020809
| Neoadjuvant Atezolizumab in Cutaneous Melanoma | | treatment | 1 | recruiting |
| NCT05520099
| Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | No drug interventions | Not Available | Not Available | recruiting |
| NCT03761017
| MGD019 DART® Protein in Unresectable/Metastatic Cancer | | treatment | 1 | active_not_recruiting |
| NCT02831634
| A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes (NeoEpitope) | No drug interventions | other | Not Available | completed |
| NCT06319196
| Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma | | treatment | 2 | recruiting |
| NCT04792463
| Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome | No drug interventions | Not Available | Not Available | recruiting |
| NCT05283330
| Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | No drug interventions | treatment | 1 | recruiting |
| NCT02355574
| 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results | No drug interventions | Not Available | Not Available | terminated |
| NCT04253080
| Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors | No drug interventions | diagnostic | Not Available | recruiting |
| NCT05086692
| A Beta-only IL-2 ImmunoTherapY Study | | treatment | 1 / 2 | recruiting |
| NCT05059444
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | No drug interventions | Not Available | Not Available | recruiting |
| NCT05578872
| A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). | | treatment | 1 / 2 | recruiting |
| NCT03611868
| A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | | treatment | 1 / 2 | recruiting |
| NCT03699995
| MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma | | screening | Not Available | recruiting |
| NCT01942603
| Minimal SN Tumor Burden | No drug interventions | Not Available | Not Available | active_not_recruiting |
| NCT02355587
| Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes | No drug interventions | Not Available | Not Available | terminated |
| NCT04702854
| Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma | No drug interventions | diagnostic | Not Available | recruiting |
| NCT05576077
| A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors | | treatment | 1 | recruiting |
| NCT02288897
| PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma | | treatment | 3 | terminated |
| NCT05628883
| Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | | treatment | 1 | recruiting |
| NCT03843593
| A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery | No drug interventions | Not Available | Not Available | completed |
| NCT05675709
| Enhancing Skin Cancer Early Detection and Treatment in Primary Care | No drug interventions | screening | Not Available | enrolling_by_invitation |
| NCT03947385
| Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | | treatment | 1 / 2 | recruiting |
| NCT04551352
| A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | | treatment | 1 | completed |
| NCT06223659
| EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers | | treatment | 2 | recruiting |
| NCT02129075
| A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma | | treatment | 2 | completed |
| NCT04778449
| Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma | No drug interventions | Not Available | Not Available | recruiting |
| NCT03620019
| Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma | | treatment | 2 | completed |
| NCT03628417
| Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous Metastases | No drug interventions | supportive_care | Not Available | completed |
| NCT02791334
| A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | | treatment | 1 | active_not_recruiting |
| NCT04830124
| Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6 | | treatment | 2 | recruiting |
| NCT04274816
| Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma | | treatment | 1 | completed |
| NCT01729663
| Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients | | treatment | 2 / 3 | unknown_status |
| NCT05571839
| A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors | No drug interventions | treatment | 1 | recruiting |
| NCT02519322
| Neoadjuvant and Adjuvant Checkpoint Blockade | | treatment | 2 | completed |
| NCT05669430
| A Study of GV20-0251 in Patients With Solid Tumor Malignancies | No drug interventions | treatment | 1 | recruiting |
| NCT03767348
| Study of RP1 Monotherapy and RP1 in Combination With Nivolumab | | treatment | 2 | recruiting |
| NCT05482074
| Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | | treatment | 2 | withdrawn |
| NCT01444560
| miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi | No drug interventions | Not Available | Not Available | completed |
| NCT04625491
| Location of Lower Limb Cutaneous Melanomas as a Prognostic Factor. | No drug interventions | Not Available | Not Available | unknown_status |
| NCT04706962
| TH1902 in Patients With Advanced Solid Tumors | No drug interventions | treatment | 1 | recruiting |
| NCT04042480
| A Study of SGN-CD228A in Advanced Solid Tumors | No drug interventions | treatment | 1 | terminated |
| NCT02968680
| Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma | | diagnostic | 1 | terminated |
| NCT05544929
| A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | | treatment | 1 | recruiting |
| NCT00679289
| Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma | | treatment | 2 | completed |
| NCT05253872
| The MELAcare Study: A New Method for Surveillance of Melanoma Patients | No drug interventions | health_services_research | Not Available | recruiting |
| NCT03633110
| Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | | treatment | 1 / 2 | completed |
| NCT05358938
| Exercise to Boost Response to Checkpoint Blockade Immunotherapy | | treatment | 0 | active_not_recruiting |
| NCT03842943
| Neoadjuvant Combination Immunotherapy for Stage III Melanoma | | other | 2 | recruiting |
| NCT04789421
| Advanced Non-invasive Diagnostics for Early Cutaneous Tumor Diagnosis, Clinical-therapeutic and Economic Management | No drug interventions | diagnostic | Not Available | completed |